Lastly, it was shown that reported that FGFR1 was upregulated in clinical prostate tumor samples, and treatment with tyrosine kinase inhibitors (TKIs) showed promising antitumor effects depending on FGFR1 expression [27]. Here, FGFR1 is linked to prostate neoplasm.